Skip to main content
. 2021 Oct 1;8:715728. doi: 10.3389/fmolb.2021.715728

FIGURE 6.

FIGURE 6

In the TARGET and ICGC cohorts, high and low-risk patients and targeted drug sensitivity. (A) Axitinib (B) Motesanib (C) Dasatinib (D) Nilotinib (E) Erlotinib (F) Pazopanib (G) Lapatinib (H) Saracatinib.